• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Coty Strengthens Consumer Beauty Business With Senior Talent

    12/2/20 3:00:00 AM ET
    $JNJ
    $COTY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $JNJ alert in real time by email

    NEW YORK--(BUSINESS WIRE)--Coty Inc. (NYSE: COTY), one of the world’s leading beauty companies and the global leader in fragrances, today announced two leaders to drive its Consumer Beauty organization. Stefano Curti will join the company as Chief Brands Officer, Consumer Beauty, while Alexis Vaganay will be promoted to Chief Commercial Officer, Consumer Beauty. The appointments come as CEO Sue Y. Nabi strengthens her leadership team, following the recent additions of Isabelle Bonfanti as Chief Commercial Officer, Luxury, and Jean-Denis Mariani as Chief Digital Officer.

    Stefano Curti joins Coty this week as Chief Brands Officer, Consumer Beauty and will be based in New York. Curti – who has a strong track record of brand building and channel expansions – will focus on strengthening the division’s brand equity, global positioning and innovation performance. He brings a wealth of senior international experience, having spent almost 30 years working in the beauty and health industry in the U.S., Europe and Latin America. Curti joins from Markwins Beauty Brands – the largest independent cosmetics company in the U.S., with established mass cosmetics brands including Physicians Formula, LORAC, Black Radiance and WetnWild – where he served as Global President. He spent 22 years at Johnson & Johnson, where he progressed through the marketing organization to the role of Global President Beauty and Baby divisions. During his time at J&J, Curti led iconic skin and personal care brands like Aveeno, Clean & Clear and Neutrogena, driving above-market sales growth and double-digit profit growth for the beauty portfolio.

    Coty also announced the promotion of Alexis Vaganay to Chief Commercial Officer, Consumer Beauty. Vaganay, who has more than 20 years’ experience in international sales and marketing, takes up his appointment this week and will be based in Coty’s Amsterdam headquarters. He will be responsible for leading Coty’s regions - in close collaboration with his Luxury counterpart - and developing Consumer Beauty’s commercial strategy to increase market share and grow revenues in color cosmetics, body care and consumer fragrances. Most recently, Vaganay was EVP, EMEA, following four years as General Manager of UK&I Luxury. Under his leadership, Coty UK&I was among the fastest growing luxury fragrance players. Prior to joining Coty in 2016, Vaganay worked at Unilever and Bic in a variety of global roles.

    Sue Y. Nabi, CEO of Coty, said, “My ambition from day one has been to quickly build a first-class leadership team. The appointment of these two leaders means we are now in great shape to re-position our portfolio of brands more clearly. Stefano’s track record and sector expertise makes him the right leader for our Consumer Beauty transformation. Alexis, likewise, is a proven leader within Coty and his deep knowledge of our business and brands makes him the perfect fit to accelerate our growth on all continents.”

    Nabi continued: “Consumer Beauty is a critical pillar of our business. In times of uncertainty, the consumer beauty industry has an essential mission: the place where people can access the latest trends and innovations, find the best quality at an accessible price and experience the diversity of all kinds of beauties. That’s why we are excited that Coty has found two beauty champions who will enable our portfolio of meaningful brands - which include COVERGIRL, Sally Hansen, Rimmel, Bourjois, adidas and David Beckham, to name a few - to truly thrive.”

    In October, Coty announced the appointment of Isabelle Bonfanti as Chief Commercial Officer, Luxury. She boasts more than 30 years’ experience in international brand development and transformation, including 17 years in L’Oréal’s Luxury division. Bonfanti was joined by Jean-Denis Mariani as Chief Digital Officer, who joined from Guerlain as Coty continues to generate record e-commerce sales across its portfolio.

    About Coty Inc.

    Coty is one of the world’s largest beauty companies with an iconic portfolio of brands across fragrance, color cosmetics, and skin and body care. Coty is the global leader in fragrance and number three in color cosmetics. Coty’s products are sold in over 150 countries around the world. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com.

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $COTY

    CompanyDatePrice TargetRatingAnalyst
    Coty Inc.
    $COTY
    8/22/2025$12.00 → $10.00Sector Perform
    RBC Capital Mkts
    Coty Inc.
    $COTY
    8/21/2025$4.25Buy → Neutral
    Citigroup
    Johnson & Johnson
    $JNJ
    7/23/2025Hold → Buy
    Erste Group
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Coty Inc.
    $COTY
    5/8/2025$5.00Buy → Hold
    Canaccord Genuity
    Coty Inc.
    $COTY
    4/17/2025Outperform → Mkt Perform
    Raymond James
    Coty Inc.
    $COTY
    4/15/2025$4.50Buy → Underperform
    BofA Securities
    Coty Inc.
    $COTY
    4/11/2025$5.65Outperform → Neutral
    Exane BNP Paribas
    More analyst ratings

    $JNJ
    $COTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts reiterated coverage on Coty with a new price target

    RBC Capital Mkts reiterated coverage of Coty with a rating of Sector Perform and set a new price target of $10.00 from $12.00 previously

    8/22/25 10:13:26 AM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Coty downgraded by Citigroup with a new price target

    Citigroup downgraded Coty from Buy to Neutral and set a new price target of $4.25

    8/21/25 8:12:50 AM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Johnson & Johnson upgraded by Erste Group

    Erste Group upgraded Johnson & Johnson from Hold to Buy

    7/23/25 8:55:43 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

    MADRID, Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at up to 10 years, when compared to standard care, routine use of Impella CP® in patients who have had a heart attack with cardiogenic shock leads to an absolute mortality reduction of 16.3% (95% CI: 0.54 to 0.92)1. When compared to the control arm at 10 years, Impella CP patients gained an average of 600 additional days alive (95% CI: 235 – 966 days)1.

    8/31/25 12:15:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AMDR Applauds Federal Court Decision to Bar Johnson & Johnson's Biosense Webster Unit from Further Violation of Anti-Trust Laws in a Win for Hospitals, Patients, and the Environment

    Yesterday Court Issued Final Injunction After Jury Finds that Biosense Webster's Unlawful, Anti-Competitive Practices Forced Hospitals to Purchase More Costly, Wasteful Products The Association of Medical Device Reprocessors (AMDR) announced that Judge James Selna of the U.S. District Court for the Central District of California has issued a permanent injunction against Johnson & Johnson's (NYSE: JNJ) Biosense Webster (BSW) medical device unit for unlawful, anti-competitive conduct. The ruling prohibits BSW from blocking hospitals' access to safe, lower-cost, FDA-regulated reprocessed cardiac catheters. The decision follows a jury verdict ordering BSW to pay plaintiff Innovative Health, L

    8/28/25 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coty Reports FY25 and Q4 Results; Targets Sequential LFL and EBITDA Trend Improvement in FY26, Returning to Growth in 2H26

    Q4 Results In Line with Expectations and Guidance Delivered FY25 Gross Margin Expansion Despite Pressure on Revenue FY26 Trend Improvement Expected to be Fueled by Blockbuster Launches and Major Push into Fragrance Mists Re-Establishing Baseline for Consistent Growth Following 4 Years of Momentum and a More Challenging CY25 Regulatory News: Coty Inc. (NYSE:COTY) (PARIS:COTY) ("Coty" or "the Company") today announced its results for the full fiscal year 2025 and the fourth quarter, ended June 30, 2025. Against a complex 2025 backdrop, Coty delivered Q4 in line with expectations, expanded FY25 gross margin, and initiated a multi-pronged plan to fuel operational and financial trend i

    8/20/25 4:30:00 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    $JNJ
    $COTY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mercier Laurent bought $61,017 worth of shares (15,500 units at $3.94), increasing direct ownership by 4% to 405,216 units (SEC Form 4)

    4 - COTY INC. (0001024305) (Issuer)

    8/28/25 6:30:00 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Chief People & Purpose Officer Srinivasan Priya bought $115,200 worth of shares (30,000 units at $3.84), increasing direct ownership by 400% to 37,509 units (SEC Form 4)

    4 - COTY INC. (0001024305) (Issuer)

    8/26/25 6:53:22 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Chief Executive Officer Nabi Sue bought $1,018,160 worth of shares (260,000 units at $3.92), increasing direct ownership by 0.82% to 32,127,286 units (SEC Form 4)

    4 - COTY INC. (0001024305) (Issuer)

    8/26/25 6:49:51 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    $JNJ
    $COTY
    SEC Filings

    View All

    SEC Form N-PX filed by Johnson & Johnson

    N-PX - JOHNSON & JOHNSON (0000200406) (Filer)

    8/26/25 4:27:56 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Coty Inc.

    10-K - COTY INC. (0001024305) (Filer)

    8/21/25 4:43:00 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Coty Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - COTY INC. (0001024305) (Filer)

    8/20/25 4:32:29 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    $JNJ
    $COTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mercier Laurent bought $61,017 worth of shares (15,500 units at $3.94), increasing direct ownership by 4% to 405,216 units (SEC Form 4)

    4 - COTY INC. (0001024305) (Issuer)

    8/28/25 6:30:00 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Chief People & Purpose Officer Srinivasan Priya bought $115,200 worth of shares (30,000 units at $3.84), increasing direct ownership by 400% to 37,509 units (SEC Form 4)

    4 - COTY INC. (0001024305) (Issuer)

    8/26/25 6:53:22 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Chief Executive Officer Nabi Sue bought $1,018,160 worth of shares (260,000 units at $3.92), increasing direct ownership by 0.82% to 32,127,286 units (SEC Form 4)

    4 - COTY INC. (0001024305) (Issuer)

    8/26/25 6:49:51 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    $JNJ
    $COTY
    Financials

    Live finance-specific insights

    View All

    Coty Reports FY25 and Q4 Results; Targets Sequential LFL and EBITDA Trend Improvement in FY26, Returning to Growth in 2H26

    Q4 Results In Line with Expectations and Guidance Delivered FY25 Gross Margin Expansion Despite Pressure on Revenue FY26 Trend Improvement Expected to be Fueled by Blockbuster Launches and Major Push into Fragrance Mists Re-Establishing Baseline for Consistent Growth Following 4 Years of Momentum and a More Challenging CY25 Regulatory News: Coty Inc. (NYSE:COTY) (PARIS:COTY) ("Coty" or "the Company") today announced its results for the full fiscal year 2025 and the fourth quarter, ended June 30, 2025. Against a complex 2025 backdrop, Coty delivered Q4 in line with expectations, expanded FY25 gross margin, and initiated a multi-pronged plan to fuel operational and financial trend i

    8/20/25 4:30:00 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on September 9, 2025 to shareholders of record at the close of business on August 26, 2025. The ex-dividend date is August 26, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely po

    7/16/25 6:25:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

    2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* 2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and adjusted EPS of $2.77 Significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA Strong operational performance and favorable foreign exchange results in Company increasing full year estimated reported sales5 guidance at the midpoint b

    7/16/25 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Leadership Updates

    Live Leadership Updates

    View All

    Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

    6/10/25 4:51:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

    WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines

    3/25/25 1:11:06 PM ET
    $JNJ
    $TVGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Coty Hosts Expert Panel to Bust Beauty Myths and #UndefineBeauty

    Experts discuss the impacts of restrictive beauty standards Urges major English dictionary publishers to revise outdated definitions of beauty Invites the public to sign the #UndefineBeauty petition at change.org Coty (NYSE:COTY) (PARIS:COTY), one of the world's largest beauty companies, with an iconic portfolio of brands across fragrance, color cosmetics, skin and body care, hosted a cross-industry roundtable to discuss restrictive beauty ideals and definitions. As the next chapter of the award-winning #UndefineBeauty campaign, the panel debunks beauty myths and includes perspectives on neuroscience, art, social media, sociology, and mental health, and underscores the need for colle

    3/18/25 7:00:00 AM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    $JNJ
    $COTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    1/30/24 12:46:49 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care